Metformin HCl CAS 1115-70-4

Purity 99% Metformin HCl / Hydrochloride Pharmaceutical Raw Materials CAS 1115-70-4 For Anti-Diabetic

Basic Info.:

Metformin HCL
Metformin Hydrochloride; 3-(diaminomethylidene)-1,1-dimethylguanidine hydrochloride
CAS NO.:1115-70-4
EINECS: 214-230-6
Formula:C4H12ClN5
Molecular Weight:165.6246
Melting Point:220 ~ 225 ºC.
Appearance: white crystalline powder; odorless. soluble in water, dissolved in methanol, slightly soluble in ethanol, insoluble in chloroform or ether.
Absorption coefficient of this product, accurately weighed, dissolved in water and diluted quantitatively per 1ml solution containing 5μg. According to the spectrophotometric determination of absorbance at 233nm wavelength, the absorption coefficient of 778 ~ 818

Description:

Metformin hydrochloride is the first choice of first-line hypoglycemic agents, this class of drugs do not stimulate pancreatic β-cells, almost no effect on normal people, and type 2 diabetes significantly hypoglycemic effect. It does not affect insulin secretion, mainly through the promotion of peripheral tissue uptake of glucose, gluconeogenesis inhibition, reduce hepatic glycogen output, delayed glucose absorption in the intestine, thereby reducing the role of blood sugar.

Usage:

This product is a fall blood sugar medicine.This product can reduce fasting and postprandial hyperglycemia in patients with type 2 diabetes, HbAlc fell by 1% ~ 1%,
the product fall blood sugar mechanism may be:
(1) increase the surrounding tissue sensitivity to insulin, increase the glucose using insulin mediated.
(2) increase the glucose utilization in non insulin dependent organizations, such as the brain, blood cells, renal medulla, intestines, skin, etc.
(3) inhibitory effect of dysplasia of hepatic glycogen, and reduced glycogen output.
(4) inhibition of intestinal wall cells to absorb glucose.

Applications:

1. Metformin, is an antidiabetic medication which is taken by mouth. It is the first-line drug of choice for the treatment of type 2 diabetes, in particular, in overweight and obese people and those with normal kidney function.Its use in gestational diabetes has
been limited by safety concerns. It is also used in the treatment of polycystic ovary syndrome, and has been investigated for other diseases where insulin resistance may be an important factor. Metformin works by suppressing glucose production by the liver
.
2. Limited evidence suggests metformin may prevent the cardiovascular and possibly the cancer complications of diabetes.It
helps reduce LDL cholesterol and triglyceride levels and is not associated with weight gain; in some people, it promotes weight loss.Metformin is one of only two oral antidiabetics in the World Health Organization Model List of Essential Medicines (the other being glibenclamide)

3. Metformin is primarily used for type 2 diabetes, but is increasingly being used in polycystic ovary syndrome,non-alcoholic fatty liver disease (NAFLD)and premature puberty,three other diseases that feature insulin resistance; these indications are still considered experimental. The benefit of metformin in
NAFLD has not been extensively studied and may be only temporary;although some randomized controlled trials have found significant improvement with its use, the evidence is still insufficient.

COA: